A groundbreaking development in pharmaceutical research has unveiled gepotidacin as the first new antibiotic treatment for gonorrhoea in three decades, presenting significant market implications for healthcare investors. The innovation addresses
A groundbreaking development in pharmaceutical research has unveiled gepotidacin as the first new antibiotic treatment for gonorrhoea in three decades, presenting significant market implications for healthcare investors. The innovation addresses






